Pancreatic Center, Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Yangzhou Key Laboratory of Pancreatic Disease, Institute of Digestive Diseases, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Front Public Health. 2022 May 12;10:865855. doi: 10.3389/fpubh.2022.865855. eCollection 2022.
Although coronavirus disease 2019 (COVID-19) is considered to be a disease that mainly involves the respiratory system, an increasing number of studies have reported that COVID-19 patients had pancreatic enzymes (PE) elevation and even pancreatic injury. The study aims to determine the prevalence of PE elevation, and the relationship between elevated PE and prognosis in COVID-19 patients.
A comprehensive literature search was conducted according to the PRISMA guideline in PubMed, Embase, Scopus, Web of Science, and Google Scholar for studies reporting PE elevation in patients with COVID-19 from 1st January 2020 to 24th November 2021.
A total of 13 studies (24,353 participants) were included in our review. The pooled prevalence of PE elevation in COVID-19 patients was 24% (18%-31%), the pooled odds ratio (OR) of mortality was 2.5 (1.7-3.6), the pooled OR of ICU admission was 4.4 (2.8-6.8), and the pooled OR of kidney injury, respiratory failure and liver injury were 3.5 (1.6-7.4), 2.0 (0.5-8.7), and 2.3 (1.4-3.9) respectively. In addition, the subgroup analysis revealed that although PE elevated to > 3 × upper normal limit (ULN) was significantly related to the mortality (OR = 4.4, 2.1-9.4), it seemed that mild elevation of PE to 1-3 ULN also had a considerable risk of mortality (OR = 2.3, 1.5-3.5).
PE elevation was a common phenomenon in patients with COVID-19, and was associated with poor clinical outcomes. However, due to the limited numbers of included studies, the result of our study still needed to be validated.
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=295630, identifier: CRD42021295630.
尽管 2019 年冠状病毒病（COVID-19）被认为主要是一种呼吸系统疾病，但越来越多的研究报告称 COVID-19 患者的胰腺酶（PE）升高，甚至出现胰腺损伤。本研究旨在确定 COVID-19 患者中 PE 升高的患病率，以及升高的 PE 与 COVID-19 患者预后之间的关系。
根据 PRISMA 指南，在 PubMed、Embase、Scopus、Web of Science 和 Google Scholar 中全面检索了 2020 年 1 月 1 日至 2021 年 11 月 24 日期间报道 COVID-19 患者 PE 升高的文献。
共纳入 13 项研究（24353 名参与者）进行综述。COVID-19 患者中 PE 升高的总体患病率为 24%（18%-31%），死亡率的汇总优势比（OR）为 2.5（1.7-3.6），重症监护病房（ICU）入住的汇总 OR 为 4.4（2.8-6.8），肾脏损伤、呼吸衰竭和肝损伤的汇总 OR 分别为 3.5（1.6-7.4）、2.0（0.5-8.7）和 2.3（1.4-3.9）。此外，亚组分析表明，尽管 PE 升高至>3×正常值上限（ULN）与死亡率显著相关（OR=4.4，2.1-9.4），但 PE 轻度升高至 1-3 ULN 似乎也有相当大的死亡风险（OR=2.3，1.5-3.5）。
PE 升高是 COVID-19 患者的常见现象，与不良临床结局相关。然而，由于纳入研究数量有限，本研究结果仍需验证。
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=295630，标识符：CRD42021295630。
